OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
135
Results
Show all
Save search
Copy query
Show results for
Unknown
(133)
Proteomics
(1)
Metabolomics
(1)
Organisms
Homo sapiens
(1)
Repository
iProX
(1)
MetaboLights
(1)
Technology Type
Mass spectrometry
(1)
Instrument Platform
Liquid Chromatography MS - Negative (LC-MS (Negative))
(1)
Liquid Chromatography MS - Positive (LC-MS (Positive))
(1)
Publication Date
2023
(1)
2019
(1)
CHEBI ID
CHEBI:89976
(1)
CHEBI:89756
(1)
CHEBI:88400
(1)
CHEBI:138471
(1)
CHEBI:134639
(1)
CHEBI:72060
(1)
CHEBI:88658
(1)
CHEBI:136147
(1)
CHEBI:140506
(1)
CHEBI:136214
(1)
CHEBI:136195
(1)
CHEBI:136212
(1)
CHEBI:134640
(1)
CHEBI:134597
(1)
CHEBI:89775
(1)
CHEBI:89778
(1)
CHEBI:85769
(1)
CHEBI:134637
(1)
CHEBI:136101
(1)
CHEBI:85000
(1)
CHEBI:136152
(1)
CHEBI:134598
(1)
CHEBI:138448
(1)
CHEBI:136154
(1)
CHEBI:136148
(1)
CHEBI:136168
(1)
CHEBI:132543
(1)
CHEBI:88472
(1)
CHEBI:85021
(1)
CHEBI:84785
(1)
Metabolite Name
PE P-18:0/22:4
(1)
PC O-16:0/20:4
(1)
PE 16:0/22:6
(1)
PC 20:4/20:4
(1)
PC 16:1/20:4
(1)
PE 18:1/20:4
(1)
PC 16:0/14:0
(1)
PE P-16:0/20:4
(1)
PE P-18:0/20:4
(1)
DAG 18:0/20:4
(1)
TAG 16:0/18:1/18:1
(1)
TAG 16:0/18:1/20:1
(1)
TAG 16:0/16:0/20:4
(1)
TAG 16:1/16:1/18:1 & TAG 16:0/14:0/20:3
(1)
TAG 18:1/18:1/20:1
(1)
TAG 16:1/16:1/18:2
(1)
TAG 16:0/18:1/20:4
(1)
TAG 16:0/18:1/18:2
(1)
MAG 18:0
(1)
PE P-18:1/20:4
(1)
PE 18:0/20:4
(1)
PE 16:0/20:4
(1)
PC 16:0/22:6
(1)
PC 16:0/20:3
(1)
PC 16:0/18:2
(1)
PC 16:0/18:1
(1)
PC 16:0/16:0
(1)
PC 42:10
(1)
PC 32:2
(1)
PC 42:5
(1)
Release Date
2025
(25)
2023
(24)
2022
(24)
2024
(23)
2021
(13)
2020
(8)
2019
(5)
2026
(4)
2018
(4)
2017
(2)
2013
(1)
Previous
page
1 / 14
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
14
Next
page
Sort
by:
Relevance
Page size
10
SHR-A1811, a novel anti-HER2 antibody-drug conjugate with optimal drug-to-antibody ratio, efficient tumor killing potency, and favorable safety profiles.
Not available
S-EPMC12200682
|
biostudies-literature
Cite
Safety and Clinical Activity of SHR7390 Monotherapy or Combined With Camrelizumab for Advanced Solid Tumor: Results From Two Phase I Trials.
Not available
S-EPMC9847543
|
biostudies-literature
Cite
Discovery of a novel RORγ antagonist with skin-restricted exposure for topical treatment of mild to moderate psoriasis.
Not available
S-EPMC8080595
|
biostudies-literature
Cite
Efficacy and safety of camrelizumab plus famitinib in patients with previously treated non-small-cell lung cancer: a single-arm, phase II trial.
Not available
S-EPMC11694305
|
biostudies-literature
Cite
Effect of postdose fasting duration on hetrombopag olamine pharmacokinetics and pharmacodynamics in healthy volunteers.
Not available
S-EPMC7373699
|
biostudies-literature
Cite
A phase Ib study of camrelizumab in combination with apatinib and fuzuloparib in patients with recurrent or metastatic triple-negative breast cancer.
Not available
S-EPMC9528096
|
biostudies-literature
Cite
A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
Not available
S-EPMC10542255
|
biostudies-literature
Cite
A randomized, open-label, multi-center, active-controlled phase II study comparing abiraterone acetate tablets (II), an improved formulation, versus originator abiraterone acetate in patients with metastatic castration-resistant prostate cancer.
Not available
S-EPMC12065284
|
biostudies-literature
Cite
Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases (PERMEATE trial): overall survival results from a multicenter, single-arm, two-cohort, phase 2 trial.
Not available
S-EPMC11458988
|
biostudies-literature
Cite
Neoadjuvant pyrotinib, trastuzumab, and docetaxel for HER2-positive breast cancer (PHEDRA): a double-blind, randomized phase 3 trial.
Not available
S-EPMC9795751
|
biostudies-literature
Cite
Previous
page
1 / 14
You're on page
1
page
2
page
3
page
4
page
5
page
...
page
14
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets
